-
公开(公告)号:US20230126400A1
公开(公告)日:2023-04-27
申请号:US17821006
申请日:2022-08-19
Applicant: Alector LLC
Inventor: Philip KONG , Herve RHINN , Tina SCHWABE , Angie YEE , Ilaria TASSI , Muhammad Abbas ALHAWAGRI , Arnon ROSENTHAL
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc.. that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20230295297A1
公开(公告)日:2023-09-21
申请号:US18171291
申请日:2023-02-17
Applicant: Alector LLC
Inventor: Tina SCHWABE , Fracesca AVOGADRI-CONNORS , Helen LAM , Ilaria TASSI , Seung-Joo LEE , Arnon ROSENTHAL
CPC classification number: C07K16/2803 , A61P25/28 , A61K2039/505
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20190010230A1
公开(公告)日:2019-01-10
申请号:US16138761
申请日:2018-09-21
Applicant: Alector LLC
Inventor: Kate MONROE , Tina SCHWABE , Francesca AVOGADRI-CONNORS , Ilaria TASSI , Helen LAM , Arnon ROSENTHAL
Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
-
公开(公告)号:US20230312712A1
公开(公告)日:2023-10-05
申请号:US18174499
申请日:2023-02-24
Applicant: Alector LLC
Inventor: Tina SCHWABE , Eric BROWN , Philip KONG , Ilaria TASSI , Seung-Joo LEE , Arnon ROSENTHAL , Robert PEJCHAL , Nels P. NIELSON
CPC classification number: C07K16/2803 , A61P25/28 , C07K2317/71 , C07K2317/90 , C07K2317/75 , C07K2317/76 , A61K2039/505
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20230142579A1
公开(公告)日:2023-05-11
申请号:US17821010
申请日:2022-08-19
Applicant: Alector LLC
Inventor: Philip KONG , Herve RHINN , Tina SCHWABE , Angie YEE , Ilaria TASSI , Muhammad Abbas ALHAWAGRI , Arnon ROSENTHAL
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K2317/24 , C07K2317/31 , C07K2317/71
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20230024528A1
公开(公告)日:2023-01-26
申请号:US17782127
申请日:2020-12-04
Applicant: Alector LLC
Inventor: Tina SCHWABE , Ilaria TASSI , Arnon ROSENTHAL , Hua LONG , Santiago Viveros SALAZAR
Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
-
公开(公告)号:US20210079074A1
公开(公告)日:2021-03-18
申请号:US16943123
申请日:2020-07-30
Applicant: Alector LLC
Inventor: Jeonghoon SUN , Wei-Hsien HO , Muhammad A. ALHAWAGRI , Philip Ling KONG , Herve RHINN , Hua LONG , Karpagam SRINIVASAN , Ananya MITRA , Daniel P. BERMINGHAM , Klaus-Dieter HEGER , Santiago Viveros SALAZAR , Francesca CIGNARELLA , Ilaria TASSI , Tina SCHWABE , Angie Grace YEE , Arnon ROSENTHAL
IPC: C07K16/18
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20210040200A1
公开(公告)日:2021-02-11
申请号:US16965676
申请日:2019-01-31
Applicant: Alector LLC
Inventor: Philip KONG , Herve RHINN , Tina SCHWABE , Angie YEE , Ilaria TASSI , Muhammad Abbas ALHAWAGRI , Arnon ROSENTHAL
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20240076362A1
公开(公告)日:2024-03-07
申请号:US18310207
申请日:2023-05-01
Applicant: Alector LLC
Inventor: Jeonghoon SUN , Wei-Hsien HO , Muhammad A. ALHAWAGRI , Philip Ling KONG , Herve RHINN , Hua LONG , Karpagam SRINIVASAN , Ananya MITRA , Daniel P. BERMINGHAM , Klaus-Dieter HEGER , Santiago Viveros SALAZAR , Francesca CIGNARELLA , Ilaria TASSI , Tina SCHWABE , Angie Grace YEE , Arnon ROSENTHAL
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号:US20230159637A1
公开(公告)日:2023-05-25
申请号:US17801776
申请日:2021-02-23
Applicant: Alector LLC , Washington University
Inventor: Francesca CIGNARELLA , Fabia FILIPELLO , Bryan BOLLMAN , Arnon ROSENTHAL , Tina SCHWABE , Ilaria TASSI , Laura PICCIO
CPC classification number: C07K16/2803 , A61P25/28 , A61K2039/505
Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
-
-
-
-
-
-
-
-
-